Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive Supplemental or secondary. In the context of Parkinson's, adjunctive medications are used to enhance the effects of levodopa. treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Parkinson’s Foundation Invests $500,000 in Community-Driven Clinical Research To Ease Cognition, Sleep and Fatigue in Parkinson’s
Monday, February 27, 2017

Five New Awards Address Unmet Needs

New York, NY and Miami, FL — The Parkinson’s Foundation has awarded $500,000 for translational research grants to address critical unmet needs in Parkinson’s disease.  The investments jumpstart practical solutions to ease difficulties related to cognition, fatigue and sleep, all of which are debilitating yet under-recognized symptoms in Parkinson’s.

The Parkinson's Foundation’s Moving Day® Walks Fund Local Parkinson’s Programs in 2017
Monday, February 13, 2017

$13.7 million dollars raised over five years
 

Young New Yorkers for the Fight Against Parkinson’s Committee and the Parkinson’s Foundation Celebrate the 10th Anniversary of Celebrate Spring New York Wednesday, April 5, 2017
Friday, February 10, 2017

The 10th Anniversary of Celebrate Spring New York will take place on Wednesday, April 5, 2017 at Lavo located at 39 East 58th Street between Madison and Park Avenues.  The event is hosted by the Young New Yorkers for the Fight Against Parkinson’s and the Parkinson’s Disease Foundation (PDF), a division of the Parkinson’s Foundation.

Parkinson’s Foundation Designates NewYork-Presbyterian/Columbia, Rush University Medical Centers as Parkinson’s Care ‘Centers of Excellence’
Monday, February 6, 2017

As foundation continues to invest in programs to improve the lives of Parkinson’s patients, designation of new Centers of Excellence further expand expert care network
 

Local Residents to Host Scotch & Sangria for Parkinson’s Research at Sear House in Closter, NJ, on Thursday, March 2
Monday, January 30, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Parkinson's Foundation Appoints John L. Lehr as Chief Executive Officer
Tuesday, January 10, 2017

 Lehr Charged with Advancing Foundation’s Mission to Accelerate the Science and Care for Parkinson’s Disease
 

The National Parkinson Foundation Announces Initiative to Further Define Stages of Parkinson’s Disease
Monday, January 9, 2017

Currently, there is no one definition of what it means to have advanced Parkinson’s disease
 

Initiative will support the creation of a tool to help physicians assess changes in the disease
 

Apply to the Parkinson’s Foundation People with Parkinson's Advisory Council by Monday, December 19
Monday, November 21, 2016

Are you interested in helping the Parkinson’s Foundation (PF) work toward a world without Parkinson’s? Apply to the People with Parkinson's Advisory Council by Monday, December 19.

In August, the Parkinson’s Disease Foundation and the National Parkinson Foundation merged to form the Parkinson’s Foundation. We are seeking advisors from the community to help us kick off a new and exciting era in the Parkinson’s community.

The Parkinson’s Foundation Celebrates the Life of Janet Reno
Monday, November 7, 2016

MIAMI and NEW YORK — Today we mourn the loss and celebrate the life of Janet Reno, a longtime friend of the Parkinson’s Foundation. Ms. Reno passed away at age 78 from complications of Parkinson’s disease. She was diagnosed in 1995, while still serving as the first female Attorney General of the United States. Despite her diagnosis, Ms. Reno continued in this role until 2000.

National Parkinson Foundation Expands Expert Care Network in Italy
Wednesday, November 2, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, announced today a new partnership with the Fresco Institute Italia to improve the quality of Parkinson’s care in Italy. The NPF Center of Excellence global network embodies the world’s leading Parkinson’s specialists focused on changing the course of Parkinson’s disease (PD). 

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.